US 12,071,673 B2
Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
Mark Pimentel, Los Angeles, CA (US); Ruchi Mathur, Los Angeles, CA (US); and Christopher Chang, Los Angeles, CA (US)
Assigned to Cedars-Sinai Medical Center, Los Angeles, CA (US)
Filed by Cedars-Sinai Medical Center, Los Angeles, CA (US)
Filed on Nov. 25, 2019, as Appl. No. 16/694,845.
Application 15/043,223 is a division of application No. 14/211,197, filed on Mar. 14, 2014, granted, now 9,289,418, issued on Mar. 22, 2016.
Application 16/694,845 is a continuation of application No. 15/810,891, filed on Nov. 13, 2017, granted, now 10,519,515.
Application 15/810,891 is a continuation of application No. 15/043,223, filed on Feb. 12, 2016, granted, now 9,845,511, issued on Dec. 19, 2017.
Claims priority of provisional application 61/792,687, filed on Mar. 15, 2013.
Prior Publication US 2020/0087711 A1, Mar. 19, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/689 (2018.01); A61K 31/137 (2006.01); A61K 31/155 (2006.01); A61K 31/22 (2006.01); A61K 31/337 (2006.01); A61K 31/351 (2006.01); A61K 31/357 (2006.01); A61K 31/366 (2006.01); A61K 31/40 (2006.01); A61K 31/404 (2006.01); A61K 31/4164 (2006.01); A61K 31/437 (2006.01); A61K 31/454 (2006.01); A61K 31/47 (2006.01); A61K 31/505 (2006.01); A61K 31/55 (2006.01); A61K 31/7036 (2006.01); A61K 31/7048 (2006.01); A61K 35/741 (2015.01); A61K 45/06 (2006.01)
CPC C12Q 1/689 (2013.01) [A61K 31/137 (2013.01); A61K 31/155 (2013.01); A61K 31/22 (2013.01); A61K 31/337 (2013.01); A61K 31/351 (2013.01); A61K 31/357 (2013.01); A61K 31/366 (2013.01); A61K 31/40 (2013.01); A61K 31/404 (2013.01); A61K 31/4164 (2013.01); A61K 31/437 (2013.01); A61K 31/454 (2013.01); A61K 31/47 (2013.01); A61K 31/505 (2013.01); A61K 31/55 (2013.01); A61K 31/7036 (2013.01); A61K 31/7048 (2013.01); A61K 35/741 (2013.01); A61K 45/06 (2013.01); C12Q 2600/106 (2013.01)] 5 Claims
 
1. A method for treating a human subject with constipation or constipation predominant irritable bowel syndrome (C-IBS), comprising:
subjecting a biological sample from the subject to detect a methanogen quantity that is higher than a reference value of 10,000 cfu per ml of the biological sample, wherein the biological sample is stool and the analysis comprises using quantitative polymerase chain reaction (qPCR);
identifying the human subject as having a quantity of methanogen that is higher than the reference value; and
administering an effective amount of lovastatin to the human subject having the quantity of the methanogen that is higher than the reference value.